DocumentsDate added
Research article
R. Sangeetha Kumari1,*, V.Kaviyarasan2
Affiliation:-
1Research Scholar, 2Assistant Professor, CAS in Botany, University of Madras, Guindy campus, Chennai –600025,India
2Assistant Professor,CAS in Botany, University of Madras, Guindy campus, Chennai – 600 025.
The name of the department(s) and institution(s) to which the work should be attributed:
CAS in Botany, University of Madras, Guindy campus, Chennai –600025, India
*To whom it corresponds:-
R. Sangeetha Kumari.
Research Scholar, CAS in Botany, University of Madras, Guindy campus, Chennai –600025, India
Email: sangkumari@gmail.com, Ph: +919092875300
Abstract
The siderophores produced by fungal organisms were screened from the both culture supernatants and solid medium by the universal chrome assural assay (CAS assay). All the screened organisms are comes under the hydroxymate type of siderophores using Iron Percholate assay at 480nm. The effect of iron concentration and complexity of media has been studied for siderophore production in the edible and medicinal mushrooms Agaricus sp and Lentinus sp. The siderophore coding genes were studied using random amplification with P1 and P2 primers.
Keywords: Chrome Azurol Sulphonate (CAS); deferroxamine; hydroxymate; carboxylate; catecholates; basidiomycetes.
REFERENCES
1.D. B. Alexander, D. A. Zuberer. Use of chrome azurol S reagents to evaluate siderophore production by rhizosphere bacteria. Biology and Fertility of Soils. 1991;12: 39-45.
2.Arnow LE. Colorimetric determination of the components of 3,4-dihydroxyphenylalanine-tyrosine mixtures. J. Biol.Chem. 1937; 118:531-537.
3.Atkin CL, Neiland JB, Phaff HJ. Rhodotorulic acid from species of Leucosporidium, Rhodospondium, Rhodotorula, Sporidiobolus and Sporobolomyces, and a new alanine- containing ferrichrome from Cryptococcus meliviosu.ni. J Bacteriol. 1970; 103:722-73
4.A.L. Crumbliss,. Aqueous Solution Equilibrium and Kinetic Studies of Iron Siderophore and Model Siderophore Complexes, Handbook of Microbial Iron Chelates, G. Winkelmann, Ed., CRC Press, 1991, Chap. 7. (invited).
5.Baakza A, Vala AK, Dave BP, et al. A comparative study of siderophore production by fungi from marine and terrestrial habitats. J. Exp. Mar. Biol. Ecol. 2004; 311:1–9.
6.S. Dhungana & A.L. Crumbliss. Coordination chemistry and redox processes in siderophore-mediated iron transport. Geomicrobiology. Journal, 2005;22:87-98.
7.Fekete, F.V. Chandhoke and J. Jellison. Iron binding compounds produced by wood decaying basidiomycetes. Appl.Environ.Microbiol.1989; 55:2720-2722.
8.Frey-Klett, P., Chavatte, M, Clausse, M.L., Courrier, S, Le Roux, C, Raaijmakers, J, Martinotti, M.G., Pierrat, J.C. and Garbaye, J. Ectomycorrhizal symbiosis affects functional diversity of rhizosphere fluorescent pseudomonads. New phytologist. 2005; 165: 317-328.
9.Hu, C. J., C. Bai, X. D. Zheng, Y. M. Wang, and Y. Wang. Characterization and functional analysis of the siderophore-iron transporter CaArn1p in Candida albicans. J. Biol. Chem. 2002;277:30598–30605.
10.Ismail A, Bedell GW, Lupan DM. Siderophore production by the pathogenic yeast Candida albicans. Biochem Biophys Res Comm.1985; 130:885–891.
11.Jelliso, J., B. Goodell, F.Fekete and V. Chandhoke, 1990. Fungal siderophores and their role in wood degradation. International Research group on wood preservation DOC.NO.IRG/WP/1442. IRG Secretariat, Stockholm, Sweden. 16PP.
12.Martin JD, Ito Y, Homann VV, et al. Structure and membrane affinity of new amphiphilic siderophores produced by Ochrobactrum sp. SP18. J Biol Inorg Chem. 2006;11:633–641. [PubMed]
13.Oberegger, H., M. Schoeser, I. Zadra, B. Abt, and H. Haas. SREA is involved in regulation of siderophore biosynthesis, utilization and uptake in Aspergillus nidulans. Mol. Microbiol. 2001; 41:1077–1089.
14.Reigh Geraldine, 1991. Analysis of siderophore production by Rhizobium meliloti 220-5. PhD thesis, Dublin City University.
15.Renshaw JC, Robson GD, Trinci APJ, et al. Fungal siderophores: structures, functions and applications. Mycol. Res. 2002;106:1123–1142.
16.Santose, R., N. Buisson, S. Knight, A. Dancis, J.M. Camadro, and E. Lesuisse. Haemin uptake and use as an iron source by Candida albicans: role of CaHMXI encoded haem oxygenase. Microbiology. 2003;149: 579-588.
17.Schroder, I., E. Johnson, and S.de Vries. Microbial ferric iron reductases. FEMS Microbiol. Rev.2003; 27:427–447.
18.Schwyn, B., and Neilands, J.B. Universal chemical assay for the detection and determination of siderophores. Anal Biochem. 1987; 160:47-56.
19.Steglich W, Steffan B, Stroech K, Wolf M. Pistillarin. A characteristic metabolite of Clavariadelphus pistillaris and several Ramaria species (Basidiomycetes) Z Naturforschung, C. 1984; 39C:10–12.
20.Winkelmann G. Microbial siderophore-mediated transport. Biochem Soc Trans. 2002; 30(4):691-6.
Article citation:
Sangeetha RK, Kaviyarasan V. Screening of Siderophores in Basidiomycetes. J Pharm Biomed Sci 2014; 04(04): 291-297. Available at www.jpbms.info.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Review article:
N. Lakshmidevi1,*, Khadega Yahyah A. Al-hetar1, G B Kavishankar1,2
Affiliation:-
1Department of Studies in Microbiology, University of Mysore, India
2Department of Studies in Biochemistry, University of Mysore, India
The name of the department(s) and institution(s) to which the work should be attributed:
University of Mysore, India
*To whom it corresponds:-
N. Lakshmidevi
Department of Studies in Microbiology, University of Mysore, India
Ph: +91-0821-2419739+91-0821-2419739
Abstract
Escherichia coli is a commensal bacterium but it can cause different infections for humans and animals after acquisition of virulence factor genes and with the time and by the random usage of antibiotics. It gains resistant to antibiotics that can be transmitted by E. coli to other pathogenic bacteria. Many measures and investigations should to be taken as a kind of prevention and to reduce the damages that will be caused by E. coli.
Keywords: E. coli, ESBLs, Phylogenetic Groups, Resistance Genes, Virulence Factors.
Article citation:
Lakshmidevi N, Al-hetar KY,Kavishankar GB. Extended Spectrum Beta Lactamase Producing Extraintestinal Pathogenic Escherichia coli (ESBL-ExPEC). J Pharm Biomed Sci 2014;04(04):343-355. Available at www.jpbms.info.
REFERENCES
1.Al-Jasser AM. Extended-Spectrum Beta-Lactamases (ESBLs): A Global Problem. J Kuwait Med Assoc 38. 2006;3:171-185.
2.Alobwede I, M'Zali FH, Livermore DM, Heritage J, Todd N, Hawkey P M,. CTX-M extended-spectrum β-lactamase arrives in the UK. J. Antimic.l Chemo. 2003;51: 470-471.
3.Arisoy M, Rad AY, Akan A, Akar N. Relationship between susceptibility to antimicrobials and virulence factors in pediatric Escherichia coli isolates. Int J Antimic Agen. 2008;31: 4-8.
4.Atifah MN, Loo H, Subramaniam G, Wong E, Selvi P, Ho S, Kamarulzaman A, Parasakthi N,. Faecal prevalence of extended-spectrum β-lactamase (ESBL)-producing coliforms in a geriatric population and among haematology patients. Malays J Pathol. 2005;27(2):75-81.
5.Baldy-Chudzik K, Mackiewicz P, Stosik M. Phylogenetic background, virulence gene profiles, and genomic diversity in commensal Escherichia coli isolated from ten mammal species living in one zoo. Vetmic.2008;3977.
6.Bekal S, Brousseau R, Masson K, Prefontaine G, Fairbrother J, Harel J,. Rapid Identification of Escherichia coli Pathotypes by Virulence Gene Detection with DNA Microarrays. J Clin Micro. 2003;41(5):2113–2125.
7.Blanco1 M, Alonso M, Nicolas-Chanoine M, Dahbi G, Mora A, Blanco, J, Lo´pez1 C, Corte´s P, Llagostera, M. Molecular epidemiology of Escherichia coli producing extended-spectrum b-lactamases in Lugo (Spain): dissemination of clone O25b:H4-ST131 producing CTX-M-15. J Anti Chemo. 2009;63:1135–1141.
8.Bonnet R. Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Anti Agen &Chemo.2004;48(1):1-14.
9.Bradford PA, Yang Y, Sahm D, Grope I, Gardovska D, Storch G. CTX-M-5, a novel cefotaxime-hydrolyzing β-lactamase from an outbreak of Salmonella typhimurium in Latvia. Antimic. Agen. & Chemo. 1998;42(8):1980-1984.
10.Branger C, Zamfir O, Geoffroy S, Laurans G, Arlet G, Thien HV, Gouriou S, Piacard B, Denamur E. Genetic background of Escherichia coli and extended-spectrum β- lactamase type. Eme Infec Dise. 2005;11(1):54-61.
11.Carlos C, Pires M, Stoppe N, Hachich E, Sato M, Gomes T, Amaral L, Ottoboni L. Escherichia coli phylogenetic group determination and its application in the identification of the major animal source of fecal contamination. Bio Cent Micro. 2010; 10:161.
12.Chapman TA, Wu X, Barchia I, Bettelheim K, Driesen S, Trott D, Wilson M, Chin J. Comparison of virulence gene profiles of Escherichia coli strains isolated from healthy and diarrheic swine. Appli & Envir Micro.2006;72 (7):4782–4795.
13.Chmelnitsky I, Carmeli Y, Leavitt A, Schwaber MJ, Venezia SN. CTX-M-2 and a new CTX-M-39 enzyme are the major extended in spectrum beta-lactamases multiple Escherichia coli clones isolated in Tel Aviv, Israel. Anti Agen &Chemo. 2005;49 (11): 4745-4750. 14. Chroma M, Kolar M. Genetic Methods For Detection of Antibiotic Resistance: Focus on Extended-Spectrum β-Lactamases. Biomed Pap. Med. Fac. Univ. Palaky Olomouc Czech Repup. 2010, 145(4):289-296.
15.Clermont O, Bonacorsi S, Bingen E. Rapid and simple determination of the Escherichia coli phylogenetic groups. Appli & Envir Micro. 2000; 66 (10):4555-4558.
16.Clermont O, Johnson J, Menard M, Denamur E. Determination of Escherichia coli O types by allele-specific polymerase chain reaction: application to the O types involved in human septicemia. Diag Micr & Infec Dis.2007;57:129–136.
17.Dutour C, Bonnet R, Marchandin H, Boyer M, Chanal C, Sirot D, Sirot J,. CTX-M-1, CTX-M-3, and CTX-M-14 β- lactamases from Enterobacteriaceae isolated in France. Antimic Agen & Chemo. 2001;46 (2):534-537.
18.Eckeret C, Gautier V, Saladin-Allard M, Hidri N, Verdet C, Ould-Hocine Z, Barnaud G, Delisle F, Rossier A, Lambert T, Philippon A, Alert G,. Dissemination of CTX-M-type β-lactamases among clinical isolates of Enterobacteriaceae in Paris, France. Anti Agen & Chemo. 2004; 48(4):1249-1255.
19.Eisner A, Fagan E J, Feierl G, Kessler H H, Marth E, Livermore DM, Woodford N. Emergence of enterobacteriaceae isolated producing CTX-M extended-spectrum β-lactamase in Austria. Antimi. Agen. Chemo. 2006;50(2):785-787.
20.Emody L, Pál T, Hacker J, Blum-Oehler G. Genes and proteins underlying microbial urinary tract virulence basic aspects and applications. New York. Kluw Acade Publis. 2002.
21.Escobar-Páramo P, Menac’h A, Gall T, Amorin A, Gouriou S, Picard B, Skurnik D, Denamur E. Identification of forces shaping the commensal Escherichia coli genetic structure by comparing animal and human isolates. Enviro Microb.2006; 8(11):1975–1984.
22.Gordon D, Cowling A. The distribution and genetic structure of Escherichia coli in Australian vertebrates: host and geographic effects. Microb. 2003;149:3575–3586.
23.Guibout VL, Jurand C, Bonacorsi S, Espinasse F, Guelfi MC, Duprotail F, Heym B, Bingen E, Chanoine MHN. Emergence and spread of three clonally related virulent isolated of CTX-M-15-producing Escherichia coli with variable resistance to aminoglycosdes and tetracycline in a France geriatric hospital. Anti Agen & Chemo. 2004;48(10): 3736-3742.
24.Hamelin K, Bruant G, El-Shaarawi A, Hill S, Edge TA, Fairbrother J., harel J, Maynard C, Masson L, Brousseau R. Occurrence of virulence and antimicrobial resistance genes in Escherichia coli isolates from different aquatic ecosystems within the St. Clair River and Detroit river areas. Appli & Enviro Micro. 2006;73(2):477-484.
25.Highland M, Byrne B, DebRoy C, Samitz E, Peterson T, Oslund K. Extraintestinal pathogenic Escherichia coli induced pneumonia in three kittens and fecal prevalence in a clinically healthy cohort population. J Veteri Diagno Invest.2009;21:609.
26.Ho PL, Wong RC, Chow KH, Yip K, Wong SS, Que TL. CTX-M type beta-lactamases among fecal Escherichia coli and Klebsiella pneumoniae isolates in non- hospitalized children and adults. J Micro Immun & Infect.2008;41:428-432.
27.Hoek AH A, Mevius D, Guerra B, Mullany P, Roberts AP, Aarts HJM. Acquired antibiotic resistance genes: an overview. Front. in Microb. 2011;2(203):1-27.
28.Hudault S, Spiller B, Morgan P, Servin A. Human diffusely adhering Escherichia coli expressing afa/dr adhesins that use human CD55 (Decay-Accelerating factor) as a receptor does not bind the rodent and pig analogues of CD55. Infect & Immu. 2004;72(8): 4859–4863.
29.Hull R, Bieler S, Falkow S, Hull S. Chromosomal map position of genes encoding P adhesins in uropathogenic Escherichia coli. Infect & Immun. 1985;51(2):693-695.
30.Jaureguy F, Landraud L, Passet V, Diancourt L, Frapy E, Guigon G, Carbonnelle, E, Lortholary, O, Clermont, O, Denamur, E, Picard, B, Nassif, X, Brisse, S. Phylogenetic and genomic diversity of human bacteremic Escherichia coli strains. BioM Cent Geno. 2008;9(560):1-14.
31.Jayaraman R. Antibiotic resistance: an overview of mechanisms and a paradigm shift. Curr Sci India. 2009;96:1475–1484.
32.Jeong SH, Bae IK, Kwon SB, Lee JH, Song JS, Jung HI, Sung KH, Jang SJ, Lee SH. Dissemination of transeferable CTX-M-type extended- spectrum β-Lactamase- producing Escherichia coli in Korea. J Appli Microb.2005;98:921-927.
33.Johnson J, Russo T, Tarr P, Carlino U, B. Svary J, Stell A. Molecular epidemiological and phylogenetic associations of two novel putative virulence genes, iha and iroN E. coli, among Escherichia coli isolates from patients with urosepsis. Infect & Immun.2000; 68(5):3040–3047.
34.Johnson J, Delavari P, Kuskowski M, Stell A. Phylogenetic distribution of extra intestinal virulence-associated traits in Escherichia coli. J Infect Dise. 2001;183:78–88.
35.Johnson JR, Kuskowski MA, Owens K, Gajewski A, Winokur PL. Phylogenetic origin and virulence genotype in relation to resistance to flouroquinolones and/or extended-spectrum cephalosporins and cephamycins among Escherichia coli isolates from animals and humans. J Infec Dise.2003;188:759-768.
36.Johnson J, Jelacic S, Schoening L, Clabots C, Shaikh N, Mobley H, Tarr P. The irgA homologue adhesin iha is an Escherichia coli virulence factor in murine urinary tract tnfection. Infect & Immu.2004;73(2):965–971.
37.Johnson JR, Kuskowski MA, O’Bryan TT, Colodner R, Raz R. Virulence genotype and phylogenetic origin in relation to antibiotic resistance profile among Escherichia coli urine sample isolates from Israeli women with acute uncomplicated cystitis. Anti Agen & Chemo.2005; 49(1):26-31.
38.Johnson J, Owens K, Clabots C, Weissman S, Cannon S. Phylogenetic relationships among clonal groups of extraintestinal pathogenic Escherichia coli as assessed by multi-locus sequence analysis. Micro & Infect. 2006;8:1702-1713.
39.Johnson JR, Menard M, Johnston B, Kuskowski MA., Nichol K, Zhanel G G. Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. Antim. Agen Chemo. 2009;53:2733–2739.
40.Johnson JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M. Escherichia coli sequence typeST131as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin. Infect. Dis. 2010;51:286–294.
41.Karisik E, Ellington MJ, Livermore DM, Woodford N. Virulence factors in Escherichia coli with CTX-M-15 and other extended spectrum β-lactamases in the UK. J Anti Chemo.2007;61: 54-58.
42.Kere´nyi M, Allison H, Ba´tai I, Sonnevend A, Emo¨dy L, Plaveczky N, Pa´l1 T. Occurrence of hlyA and sheA genes in extraintestinal Escherichia coli strains. J Clin Micro. 2005;43(6):2965–2968.
43.Kiratisin P, Apisarnthanark A, Laesripa C, Saifon P. Molecular characterization and epidemiology of extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumonia isolated causing health care-associated infection in Thailand, where the CTX-M family is endemic. Anti Agen & Chemo. 2008; 52(8): 2818-2824.
44.Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumonia and Serratiamarcescens. J Infec. 1983; 11: 315-317.
45.Kuntaman K, Lestari ES, Severin JA, Kershof IM, Mertaniasih NM, Purwanta, M., Hadi, U, Johnson JR, Belkum A, Verbrugh HA. Fluoroquinolone-resistant Escherichia coli, Indonesia. Emer Infect Dis. 2005;11 (9):1663-1669.
46.Lambert PA. Bacterial resistance to antibiotics: modified target sites. Adv Drug Deliv Rev.2005;57: 1471–1485.
47.Lavigne JP, Marchandin H, Delmas J, Moreau J, Bouziges N, Lecaillon E, Cavalie L, Pierre HJ, Bonnet R, Sottoo A. CTX-M β-lactamase-producing Escherichia coli in French hospitals: prevalence, molecular epidemiology, and risk factors. J Clin Micro. 2006;45(2):620-626.
48.Lavigne JP, Blanc–Potard AB, Bourg G, Moreau J, Chanal C, Bouziges N, Callaghan DO, Sotto A. Virulence genotype and nematode-killing properties of extra-intestinal Escherichia coli producing CTX-M β-lactamases. J Clin Micro & Infec Dis. 2006;12(12): 1199-1206.
49.Lecointre G, Rachdi L, Darlu P, Denamur E. Escherichia coli Molecular phylogeny using the incongruence length difference test. The Soci for Molec Bio & Evol. 1998; 15(12): 1685–1695.
50.LewisII JS, Herrera M, Wicker B, Patterson JE, Paterson JH. First report of the emergence of the CTX-M-type extended-spectrum β-lactamase (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Anti Agen & Chemo. 2007; 51(11): 4015-4021.
51.Machado E, Canton R, Baquero F, Galan JC, Rollan A, Peixe L, Coque TM. Integron content of extended-spectrum-β-lactamase-producing Escherichia coli strains over 12 years in a single hospital in Madrid, Spain. Anti Agen & Chemo. 2005; 49 (5): 1823-1829.
52.Mamlouk K, Boubaker IB, Gautier V, Vimont S, Picard B, Redjeb SB, Arlet G. Emergence and outbreak of CTX-M β-lactamase-producing Escherichia coli and Klebsiella pneumonia strains in a Tunsian hospital. J Clin Micro. 2006; 44 (11): 4049- 4056.
53.MainousIII AG, Pomeroy C. Management of antimicrobials in infectious diseases. Totowa, New Jersey: Humana Press. 2001.
54.Manges A, Tabor H, Tellis P, Vincent C, Tellier P. Endemic and epidemic lineages of Escherichia coli that cause urinary tract infections. Emer Infec Dis. 2008; 14 (10): 1575-1583.
55.Manning SD. Deadly diseases and epidemics Escherichia coli infections. USA: Chelsea House Publishers. 2004.
56.Martinez LM, Fernnandez F, Perea EJ. Relationship between Haemolysis production and resistance to fluoroqunolones among clinical isolates of Escherichia coli. J Anti Chemo. 1999; 43: 277-279.
57.McCraken M. Characterization of extended-spectrum beta-lactamases (ESBLs) in North America. University of Manitoba, Canada, 2006.
58.Meier C, Oelschlaeger TA, Merkert H, Korhonen TK, Hacker JR. Ability of Escherichia coli isolates that cause meningitis in newborns to invade epithelial and endothelial cells. J Infec & Immun. 1996; 64 (7): 2391-2399.
59.Mendonca N, Leitoe J, Manageiro V, Ferreira E, Canica M. Spread of extended-spectrum β-lactamase CTX-M-producing Escherichia coli clinical isolates in community and nosocomial environments in Portugal. Anti. Agen & Chemo. 2007; 51(6): 1946-1955.
60.Mora A, López C, Dabhi G, Blanco M, Blanco J, Alonso M, Herrera A, Mamani R, Bonacorsi S, Moulin-Schouleur M, Blanco J. Extra intestinal pathogenic Escherichia coli O1:K1:H7/NM from human and avian origin: detection of clonal groups B2 ST95 and DST59 with different host distribution. BioM Cent Micro. 2009; 9(132).
61.Moreno JE, Planells I, Prats G, Planes AM, Moreno G, Andreu A. Comparative study of Escherichia coli virulence determinants in strains causing urinary tract bacteremia versus strains causing pyelonephritis and other sources of bacteremia. Diag Micro & Infect Dis. 2005; 53: 93-99.
62.Nazareth H, Genagon SA, Russo T. Extraintestinal pathogenic Escherichia coli survives within neutrophils. Infec & Immun. 2007; 75 (6): 2776–2785.
63.Nicolle L, Association of Medical Microbiology and Infectious Diseases (AMMI) Canada Guidelines Committee.. Complicated urinary tract infection in adults. The Can J of Infect Dis & Med Micro. 2005; 16 (6): 349-360.
64.Nowicki B, Selvarangan R, Nowicki S. Family of Escherichia coli dr adhesins: decay-accelerating factor receptor recognition and invasiveness. J Infec Dis. 2001; 183 (1): 24-27.
65.Nowrouzian F, Adlerberth I, Wold A. Enhanced persistence in the colonic microbiota of Escherichia coli strains belonging to phylogenetic group B2: role of virulence factors and adherence to colonic cells. Micro& Infect. 2006; (8):834-840.
66.Obata-Yasuoka M, Ba-Thein W, Tsukamoto T, Yoshikawa H, Hayashi H, Vaginal Escherichia coli share common virulence factor profiles, serotypes and phylogeny with other extra intestinal E. coli. J Microb. 2002; 148: 2745–2752.
67.Oelschlaeger TA, Dobrindt U, Hacker J. Pathogenicity islans of uropathogenic E. coli and the evolution of virulence. Inter J Anti Agen. 2002; 19: 517-521.
68.Pagani L, Amico ED, Migliavacca R, D’Andrea MM, Giacobone E. Amicosante G, Romero E, Rossolini GM. Multiple CTX-M-type extended spectrum β-lactamases in nosocomial isolates of Enterobacteriaceae from a hospital in Northen Italy. J Clin Micro. 2003; 41(9): 4264-42-69.
69.Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microb Rev. 2005; 18(4): 657-686.
70.Peirrano G, vanderBij AK, Greg- son DB, Pitout JD. Molecular epidemiology over an eleven-year period (2000-10) of extended-spectrum beta-lactamase- producing Escherichia coli causing bacteraemia in a centralized Canadian region. J. Clin .Microbiol. doi. 2011; 50(2):294-299.
71.Piatti G, Mannini A, Balistreri M, Schito AM. Virulence factors in urinary Escherichia coli strains: Phylogentic background and quinolone and flouroquinolone resistance. J Clin Microb. 2007;46 (2):480-487.
72.Picard B, Garcia JS, Gouriou S, Duriez P, Brahimi N, Bengen D, Elion J, Denamur E. The link between phylogeny and virulence in Escherichia coli extra intestinal infection. J Infec & Immun. 1998;67(2): 546-553.
73.Pitout JDD, Laupland KB, Church DL, Menard ML, Johnson JR. Virulence factors of Escherichia coli isolates that produce CTX-M type extended-spectrum β-lactamases. Anti Agen & Chemo. 2005; 49(11):4667-4670.
74.Pitout JDD, Laupland KB. Extended spectrum beta-lactamases producing Enterobacteriaceae: an emerging public health concern. Lancet. Infect. Dis. 2008; 8:159-166.
75.Pitout JD, Gregson, DB, Camp-bell L, Laupland KB. Molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to2007: emergenceofclone ST131 as a cause of community-acquired infections. Anti. Agen Chemo. 2009; 53:2846–2851.
76.Pitout JD. Extra-intestinal pathogenic Escherichia coli: a combination of virulence with antibiotic resistance. Anti Agen & Chemo. 2012; 3(9): 1-7
77.Poirel L, Kampfer P, Nordamann P. Chromosome encoded ambler class A β-lactamases of Kluyvera Georgiana, a probable progenitor of a subgroup of CTX-M extended-spectrum β-lactamases. Anti Agen & Chemo. 2002;46(12) 4038-4040.
78.Prelog M, Fille M, Prodinger W, Grif K, Brunner A, Würzner R, Zimmerhackl LB. CTX-M-1-Related Extended-Spectrum Beta-Lactamases Producing Escherichia coli: so far a Sporadic Event in Western Austria. J. of Infect. 2008;36 (4):362-367.
79.Queener SF, Webber JA, Queener SW. Beta-lactam antibiotics for clinical use. New York. Marcel Dekker. 1986.
80.Rasheed JK, Jay C, Metchock B, Berkowitz F, Weigel L, Crellin J, Steward C, Hill B, Medeiros AA, Tenover FC. Evolution of extended spectrum β- lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia. Anti Agen & Chemo. 1997;41(3):646-653.
81.Rogers BA, Sidjabat HEm, Patreson DL. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J. Anti. Chemo. 2011; 66:1-14.
82.Russo T, Carlino U, Mong A, Jodush S. Identification of genes in an extraintestinal isolate of Escherichia coli with increased expression after exposure to human urine. Infect & Immun. 1999; 67(10): 5306.
83.Russo TA, Johnson JR,. Medical and economic impact of extra-intestinal Infections Due to Escherichia coli: focus on an increasingly important endemic problem. J Mic.& infect. 2003; 5: 449-456.
84.Ryan KJ, Ray CG. Sherris medical microbiology: An introduction to infectious diseases. USA. The McGraw-Hill Companies.2004.
85.Ryoo NH, Kim E, Hong SG, Park YJ, Lee K, Bae IK, Song EH, Jeong SH. Dissemination of SHV-12 and CTX- M-type extended-spectrum β-lactamases among clinical isolates of Escherichia coli and Klebsiella pneumoniae and emergence of GES-3 in Korea. J Anti Chemo. 2005;56:698-702.
86.Sabate M, Prats G, Moreno E, Balleste E, Blanch AR, Andreu A. Virulence and antimicrobial resistance profiles among Escherichia coli strains isolated from human and animal wastewater. Res Microb. 2008;159:288-293.
87.Schouleur MM, Reperant M, Laurent S, Laurent S, Bree A. Extra-intestinal pathogeneic Escherichia coli strains of avian and human origin: link between phylogenetic relationships and common virulence patterns. J Clin Microb. 2007;45(10):3366-3376.
88.Schwertmann A, Schroten H, Hacker J, Kunz C. S-fimbriae from Escherichia coli bind to soluble glycoproteins from human milk. J Ped Gastr & Nutr. 1999;28(3):257-63.
89.Servin AL. Pathogenesis of afa/dr diffusely adhering Escherichia coli. clin Microb Rev. 2005; 18 (2):264–292.
90.Sharma S, Bhat G, Shenoy S. Virulence factors and drug resistance in Escherichia coli isolated from Extra-intestinal infections. Indi J Med Microb. 2007; 25 (4):369-373.
91.Siu LK, Lu PL, Hsueh PR, Lin MF, Chang SC, Luh KT, Ho M, Lee CY,. Bacteremia due to extended- spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a pediatric oncology ward: clinical features and identification of different plasmids carrying both SHV-5 and TEM-1 genes. J Clin Microb. 1999;37(12):4020-4027.
92.Subramaian G, Palasubramanian S, Navartanam P. SHV-5 extended spectrum β-lactamases in clinical isolates of Escherichia coli in Malaysia. Indi J Med Microb. 2006;24(3):205-207.
93.Talaro KP, Talaro A. Foundations in microbiology: Basic principles. New York. McGraw-Hill, 2002
94.Tarr P, Bilge S, Vary J, Jelacic S, Habeeb H, Ward T, Baylor M, Besser T. Iha: a novel Escherichia coli O157:H7 adherence-conferring molecule encoded on a recently acquired chromosomal island of conserved structure. Infect Immun. 1999;68(3): 1400-1407.
95.Todar, K., 2008. Pathogenic E. coli. U.S.A. (www.textbookofbacteriology.net).
96.Tofteland E, Haldorson B, Dahl KH, Simonsen GS, Steinbakk M, Walsh TR, Sundsfjord A, The Norwegian ESBL study group. Effect of phenotype and genotype on methods for detection of extended-spectrum-β-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway. J Clin Microb. 2006;45(1): 199-205.
97.Vimont S, Aubert D, Mazoit JX, Poirel L, Nordman P. Broad spectrumβ Lactams for treating experimental peritonitis in mice due to Escherichia coli Producing plasmid-encoded cephalosporinases. J Anti Chemo. 2007;60:1045-1050.
98.Wiles T, Kulesus R, Mulvey M,.Origins and virulence mechanisms of uropathogenic Escherichia coli. Exper. & Molec. Patho. 2008;85(1):9-11.
99.Woodford N, Ward ME, Kaufmann ME, Turton J, Fagan EJ, James D, Johnson AP, Pike R, Warner M, Cheasty T, Pearson A, Harry S, leach JB, Loughrey A, Lowes JA, Warren RE, Livermore DM. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β-lactamases in the UK. J Antimic. Chemo. 2004;54:735-743.
100.Yu Y, Ji S, Chen,Y, Zhou W, Wei Z, Li L, Ma Y. Resistance of strain producing extended-spectrum β-lactamases and genotype. J Infec. 2007; 54:53-57.
101.Zhang L, Foxman B, Marrs C. Both urinary and rectal Escherichia coli isolates are dominated by strains of phylogenetic group B2. J Clin Microb, 2002; 40(11):3951–3955.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Copyright © 2014 Lakshmidevi N, Al-hetar KY,Kavishankar GB. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original Article
Bagbi Baribefe M1,* , Omotoso Abayomi E2, Chiagozie Ochuba3
Affiliation:-
1,3Department of Clinical Pharmacy and Experimental Pharmacology, Faculty of Pharmaceutical Sciences, University of Port-Harcourt, Nigeria
2Department of Medicinal and Pharmaceutical Chemistry, University of Port-Harcourt, Nigeria
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Clinical Pharmacy and Experimental Pharmacology, Faculty of Pharmaceutical Sciences, University of Port-Harcourt, Nigeria
Department of Medicinal and Pharmaceutical Chemistry, University of Port-Harcourt, Nigeria
*To whom it corresponds:-
Dr. Bagbi Baribefe M.
Department of Clinical Pharmacy and Experimental Pharmacology, Faculty of Pharmaceutical Sciences, University of Port-Harcourt, Nigeria
Abstract
This study evaluated the quality of seven commercially available (European or Asian sourced) Atorvastatin Calcium(ATV-Ca) tablets products marketed in Southern-Nigeria, with a view to determine their interchangeability in clinical practice. Survey of the assessed Atorvastatin brands was carried out in some southern-Nigeria cities based on their prices. Drug products’ quality assessment included visual examination for their organoleptic properties; tests for weight variation, friability, hardness, disintegration time, dissolution profile and assay for Atorvastatin content. A validated UV-Vis Spectro-photometric method was employed in the assay. Findings indicated that the European sourced samples were 2 to 3 times more expensive than the Asian sourced samples. All brands complied with the official specifications for friability and disintegration time, but sample F failed the test for weight variation (%). Sample C and F also failed the test for tablet hardness. Assay results revealed that with the exception of samples D, F and G, other samples contained >90% (w/w) of labeled potency. Four out of the seven samples attained 70% dissolution within 40min. Comparison of the dissolution profile of the different samples were carried out by model-independent approaches of difference factor(f1), similarity factor(f2) and dissolution efficiency (% DE). These results demonstrated that the European sourced Atorvastatin calcium tablets may after all not be interchangeable with those sourced from Asia.
Keywords: Atorvastatin calcium; Interchangeability; Similarity factor and European.
Article citation:
Bagbi Baribefe M, Omotoso Abayomi E, Chiagozie Ochuba. Comparative Assessment of Quality Brands of Atorvastatin Tablets Marketed in Southern Nigeria. J Pharm Biomed Sci. 2014;04(03):318-326. Available at www.jpbms.info.
REFERENCES
1.Nagaraju P, Pasumarthy, Gopal NV, Srinivas VDN and Padma SVN. Spectrophotometric methods for the determination of Atorvastatin calcium in pure and its Pharmaceutical Dosage forms. Asian J Research Chem. 1 (2):2008; 64-66.
2.The British Pharmacopoeia; The Stationary office London 2011
3.Salam WA, Dumitru. Enhancement of solubility and dissolution rate of different forms of Atorvastatin calcium in direct compression tablet formulas. Farmacia 2009;57(3):290-300.
4.United State Pharmacopoeia and National Formulary USP 34 NF 29. Convention, Mack, Easton, PA; 2011, 1949.
5.British Pharmacopoeia (2005) Volume 4, Appendix XII H A 273, Table 2.9. 5-1
6.Moshood OA, Oladapo I, Patricia NN, Olubukola OO. Quality of Brands of Atorvastatin calcium tablets marketed in Lagos, Nigeria. Int. J Pharmacy & Pharmacol. 2012;1 (1):001-007.
7.Tanjinatus OO, Ishra N, Ashraful Islam SM. Comparative in vitro Bioequivalence Analysis of some Generic tablets of Atorvastatin, a BCS class II compound. Bangladesh Pharmaceutical Journal 2011;14(1):61-66.
8.Fawzia K, Mingzhong L, Walkeria S(2013). Comparison of in vitro Dissolution Tests for commercially Available Aspirin Tablets. Dissolution technologies pp 48-58.
9.Moore JW, Hanner HH. Mathematical comparison of Dissolution profile. Pharm Tech. 1996; 20(6):64-74.
10.Costa FO, Sousa jj, Pais AACC, Formosinho SJ. Comparison of dissolution profile of Ibuprofen pellets. J Control Release 2003; 89 (2):199-212.
11.Costa P, Sousa Lobo. Modeling and comparison of dissolution profiles. J. Pharm. Sci. 2001; 13 (2):123-133.
12.Babalola CP (2004). Bioavailability and Bioequivalence (BA/BE) assessment. In Olaniyi AA et al., eds. Towards better quality assurance, 1st ed. Ibadan Nigeria, Omoadade Printing Press, 2004.
13.Adegbolagun OA, Ololade OA, Osumah SE. Comparative evaluation of the biopharmaceutical and chemical equivalence of some commercially available brands of ciprofloxacin hydrochloride tablets. Trop. J Pharm. Res. 2007; 6: 737-745.
14.Tousey MD. Tablet pro: A tablet making training resource for tablet making professional. Techceuticals.2001;4(1);1-15. www dipharma.com/TP_V4 pdf [Assessed on 09-03-2012]
15.Kalakuntla R, Veerlapati U, Chepuri M, Rapavla R. Effect of various super disintegrant on hardness, disintegration and dissolution of drug from dosage form. J Adv. Sci. Res. 2010; 1(1): 15-19.
16.Salam WA, Dumitru L. (2009) Enhancement of solubility and dissolution rate of different forms of Atorvastatin calcium in direct compression tablet formulas.Farmacia. 2009;57(3):290-300.
17.Guidance for industry. Waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms based on biopharmaceutics classification system. Silver Spring, Maryland, Department of Health and Human Services. Food and Administration Centre for Drug Evaluation and Research 2000.
18.Notes for guidance on the investigation of bioavailability and bioequivalence. London, European Agency for the evaluation of medical products, 2000 (CPMP/EWP/QWP/1401/98).
19.Zaid A, Rinno T, Jaradat N, Jodeh S, Khammash S (2013). Interchangeability between Paracetamol tablet marketed in Palestine: Is there a quality reason for a higher price? EMHJ.2013; 19(6); 542-546.
20.Dressman J, Butler J, Hempenstall J Reppas C. The BCS: Where do we go from here? Pharmaceutical Technology.2001; 25: 68-76.
21.Voegele D. Drug release in vitro- an aid in clinical trials? Methods and findings in Experimental and clinical Pharmacology.1999; 21 (1): 55-62.
22.Adegbite AI, Adegbolagun OM. Evaluation of physicochemical equivalence of three brands of commercially available Quinine sulphate tablets from South Western part of Nigeria. Afr. Health Sci. 2011; 11(2) 197-203.
23.Dissolution Testing of immediate release solid oral dosage forms; Guidance for industry, US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), US Government Printing Office: Washington, DC, 1997.
24.Anderson NH, Bauer M, Boussac N et al.,. An Evaluation of fit factor and dissolution efficiency for the comparison of in vitro dissolution profiles. J Pharm. Biomed. Anal. 1998; 17, 811-822.
25.Chiba, Y., Kohri, N., Iseki, K. and Miyazaki, K. Improvement of dissolution and bioavailability for mebendazole, an agent for human echinococcosis, by preparing solid dispersion with polyethylene glycol. Chem. Pharm. Bull. 1991; 39, 2158-2160.
26.Colhoun HM., Betteridge DJ., Durrington PN., et al - Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial; Lancet. 2004; 364:685.
27.Lea AP, McTavish D: Atorvastatin: A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs 1997; 53:828-847.
28.Ahmed S, Rasul A, Masood Z (2011). Spectrophotometry in Pharmaceutical Analysis. Germany, LAP Lambert Academic Publishing.
29.Dhabale PN, Gharge DS.Simultaneous spectrophotometric estimation of Atorvastatin and Fenofibrate in bulk drug and Dosage form by using simultaneous equation method. Int. J. of ChemTech Research. 2010; 2(1);325-328.
30.Vijya GM, Arabinda P, Shubhrajit M, Sathees SM (2013). A new method for estimating Atorvastatin in tablet with its stability studies by using RP-HPLC. Int. J. Pharm. & Ind. Res. 2013;03 (01): 27-33.
31.Wani TA, Khalil NY, Abdel-Rahman HM, Darwish IA. Novel microwell-based Spectrophotometric assay for Determination of Atorvastatin Calcium in Pharmaceutical Formulations. Chemistry Central Journal.2011; 5:57.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Copyright © 2014 Bagbi Baribefe M, Omotoso Abayomi E, Chiagozie Ochuba. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article
Sushma Katkuri1,*,Pravinpisudde1,Nithesh Kumar1,Syeda Farha Hasan2
Affiliation:-
1Assistant Professor, Department of Community Medicine, Deccan College of Medical Sciences, Hyderabad,A.P, India
2Final Year MBBS student, Deccan College of Medical Sciences, Hyderabad, A.P, India
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Community Medicine, Deccan College of Medical Sciences, Hyderabad, A.P, India
*To whom it corresponds:-
Dr Sushma Katkuri*
House No-9 Bhavya Shri Krishna Avenue
Pragati Nagar, Quthbulapur Mandal, Hyderabad-500009, A.P, India
Contact no:-+91- 9160144007
Abstract
A Study to Assess Knowledge, Attitude and Practices of Menstrual Hygiene among School Going Adolescent Girl’s in Hyderabad, India
Background: Adolescent girls constitute a vulnerable group not only with respect to their social status but also in relation to health. Menstruation is regarded as unclean or dirty in Indian society. Although it is a natural process, is linked with several misconceptions and practices which sometimes results into adverse health outcomes. Poor personal hygiene and unsafe sanitary conditions result in the girls facing many gynaecological problems Aims & Objectives: To study knowledge, attitude and practices about menstrual hygiene among adolescent girls. Materials & Methods: A community based cross sectional study was done in school going adolescent girls from a Secondary school near Deccan College of Medical Sciences, Hyderabad. A randomly selected group of 250 adolescents girl’s in the age group of 12 -15 years from class 7th -10th were included in the study. Results: The subjects were maximum in the age group of 13 years (38%) and 14years (37.2%). Almost 54% of the girl’s were aware about the menstrual cycles. 60% reported that mothers were the main source of information about menstrual cycles. Certain faulty practices were followed during menstruation like 54.4 % were not allowed to visit holy places and 45 % said that they are restricted to perform any household activities. Conclusion: The study reflects that the awareness about menstruation was good but still knowledge about certain details regarding menstruation was not known. Therefore the deficiencies can be fulfilled by providing proper information to them by school teachers, health educators and mothers.
Keywords: Adolescents; menstruation; practices; attitudes.
REFERENCES
1.WHO/UNFPA/UNICEF. Programming for Adolescent Health and Department. Report of WHO/UNFPA/UNICEF Study Group on Programming for Adolescent Health. Technical Report Series. Geneva. 1996 No. 886
2.Abera Y. Menarche, Menstruation Related Problems and Practices Among Adolescent High School Girls in Addis Ababa. Thesis of Master degree Addis Ababa University 2003/04: P.9.
3.Drakshayani D K, Venkata RP. A study on menstrual hygiene among rural adolescent girls. Indian Journal Of Medical Sciences.1994 Jun;48 (6):139-143.
4.Dasgupta A and Sarkar M. Menstrual Hygiene: How hygienic is the adolescent girl? Indian Journal of Community Medicine. 2008;33( 2):77-80.
5.Bhatia JC, Cleland J. Self Reported Symptoms of Gynaecological Morbidity and their Treatment in South India. Studies in Family planning.1995 Jul-Aug; 26(4):203-16.
6.Mehta S.(Ed.) 1995. Adolescent Girl: An Indian Perspective. New Delhi: Mamta Health Institute for Mother and Child.
7.Greene E Margaret 1997. Watering the Neighbours Garden. New Delhi: Population Council (Working Paper. No. 7).
8.Paul D 2007.A Report of an ICMR Funded Research Project: Knowledge and Practices of Adolescent Girls Regarding Reproductive Health with Special Emphasis on Hygeine during Menstruation. New Delhi: National Institute of Public Cooperation and Child Development(NIPCCD).
9.Dipali Nemade, Seema Anjenaya, and Ruplai Gujar. Impact of health education on knowledge and practices about menstruation among adolescent girls of Kalamboli Navi-Mumbai. Health and Population and Issues. 2009;32 (4):167-175.
10.Abhay Bhausaheb Mudey, Naveeta Kesharwani, Gargi Abhay Mudey, Ramchandra C Goyal A Cross-sectional Study on Awareness Regarding Safe and Hygienic Practices amongst School Going Adolescent Girls in Rural Area of Wardha District, India. Global Journal of Health Science. 2010 Oct; 2(2): 225-231.
11.Echendu Dolly Adinma, J.I.B. Adinma. Perceptions and Practices on Menstruation Amongst Nigerian Secondary School Girls. African Journal of Reproductive Health. 2008 April;12(1):74-83.
12.Rajni Dhingra, Anil Kumar and Manpreet Kour. Knowledge and Practices Related to Menstruation among Tribal (Gujjar) Adolescent Girls. Ethno-Med.2009;3(1):43-48.
13.Lakshmi G, Sambasiva Rao R, Giridhar L. Perceptions and practices regarding menstruation: A comparative study in Savara and Jatapu tribal adolescent girls in Srikakulam district. Asian Journal of Pharmaceuticals and Health sciences. 2013: July-Sept;3(3): p748-752.
14.Shabnam Omidyar, Khyrunnisa Beguam. Factors influencing hygienic practices during menses among girls from south India-A cross-sectional study. International journal of Collaborative Research on Internal Medicine & Public Health. 2010: Dec;2(12):411-423.
15.Lawan UM, Nafisa Wali Yusuf, Aisha Bala Musa. Menstruation and Menstrual hygeine amongst Adolescent School Girls in Kano, Northwestern Nigeria. African Journal of Reproductive Health.2010:Sept;14(3):201-208.
Article citation:
Sushma Katkuri, Pravin pissude, Nithesh Kumar, Syeda Farha Hasan Abedi. A Study to Assess Knowledge, Attitude and Practices about Menstrual Hygiene Among School Going Adolescent Girl’s in Hyderabad, India. J Pharm Biomed Sci 2014; 04(04):298-302. Available at www.jpbms.info.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Copyright © 2014 Sushma Katkuri, Pravin pissude ,Nithesh Kumar, Syeda Farha Hasan Abedi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Review Article:
Fuyong Jiao1,*, Xiangyang Guo2, Xianpeng Yan3, Li Wei4
Affiliation:-
1Professor, Department of Pediatrics the Shaanxi Provincial People's Hospital of Xi,an Jiaotong Univeristy, Xi,an China
2Assistant Professor, Section of pediatric Neurology, Dept. of Pediatrics the Shaanxi Provincial People's Hospital of Xi,an Jiaotong Univeristy, Xi,an China
3Department of Pediatrics the Shaanxi Provincial People's Hospital of Xi,an Jiaotong Univeristy, Xi,an China
4Department of Pediatrics the Shaanxi Provincial People's Hospital of Xi,an Jiaotong Univeristy, Xi,an China
The name of the department(s) and institution(s) to which the work should be attributed:
Section of pediatric Neurology, Department of Pediatrics, 3rd affiliated hospital, Xi,an Jiaotong University, Xi,an, China
*To whom it corresponds:
Fuyong Jiao.
Prof. and Head
Dept. of Pediatrics the Shaanxi Provincial People's Hospital of Xi,an Jiaotong Univeristy, Xi,an China
President of China Society for Prevention of Child Abuse and Neglect
Executive councilor of International Society for Prevention of Child Abuse and Neglect ( ISPCAN )
Phone: ( 86) 029 -85368194, 85521331ext2361(O)
Mail Add: No.256 youyi West Rd. Xi,an 710068 China
jiaofy@yeah.net
Abstract:
Tourette syndrome is an inherited neuropsychiatric disorder with onset in childhood, characterized by multiple motor tics and at least one vocal tic. As the diagnostic threshold and assessment methodology have moved towards recognition of milder cases, the prevalence increase gradually. Males are more likely than females to express tics. The exact cause of TS is unknown, but environmental insults interact with genetic or other risk factors to engender the specificity suggested by neuropathological findings. The treatment of TS focuses on identifying and helping the individual manage the most troubling or impairing symptoms. Knowledge, education and understanding are uppermost in management plans. New studies on large prospective cohorts of patients of different age and the identification of reliable biomarkers or environmental insults are needed.
Keywords: Tourette syndrome; environmental insults; gene; supportive environment.
REFERENCES
1.Singer HS. Tourette syndrome and other tic disorders. Handb Clin Neurol. 2011;100:641–57.
2.Robertson MM.Gilles de la Tourette syndrome: the complexities of phenotype and treatment. Br J Hosp Med . 2011;72(2):100–7.
3.Leckman JF, Zhang H, Vitale A, et al. Course of tic severity in Tourette syndrome: the first two decades. Pediatrics. 1998;102 (1 Pt 1):14–19.
4.Du JC, Chiu TF, Lee KM, et al. Tourette syndrome in children: an updated review. Pediatr Neonatol. 2010 Oct;51(5):255–64.
5.Swain JE, Scahill L, Lombroso PJ, et al. Tourette syndrome and tic disorders: a decade of progress. J Am Acad Child Adolesc Psychiatry. 2007;46(8):947–68.
6.Scahill L, Williams S, Schwab-Stone M, et al. Disruptive behavior problems in a community sample of children with tic disorders. Adv Neurol. 2006;99:184–90.
7.Bloch MH, Leckman JF. Clinical course of Tourette syndrome. J Psychosom Res. 2009 Dec;67(6):497–501.
8.Bloch M, State M, Pittenger C. Recent advances in Tourette syndrome. Curr. Opin. Neurol. 2011 Apr;24(2):119–25.
9.Lombroso PJ, Scahill L. Tourette syndrome and obsessive–compulsive disorder. Brain Dev. 2008 Apr;30(4):231–37.
10.Robertson MM. The prevalence and epidemiology of Gilles de la Tourette syndrome. Part 1: the epidemiological and prevalence studies. J Psychosom Res. 2008 Nov;65(5):461–72.
11.Cohen DJ, Jankovic J, Goetz CG, (eds). Advances in neurology, Tourette syn58drome. Lippincott, Williams & Wilkins, Philadelphia, PA. 2001.
12.Abuzzahab FE, Anderson FO. Gilles de la TS syndrome; international registry. Minnesota Medicine. 1973 Jun;56(6):492–96.
13. Scahill L. Epidemiology of Tic Disorders. Medical Letter: 2004 Retrospective Summary of TS Literature. Tourette Syndrome Association. Thefirst page (PDF), is available at archive.org without subscription. Retrieved on June 11, 2007.
14.Zohar AH, Apter A, King RA et al. Epidemiological studies. In Leckman JF, Cohen DJ. TS Syndrome—Tics, Obsessions, Compulsions: Developmental Psychopathology and Clinical Care. John Wiley & Sons, Inc., New York. 1999:177–92.
15.Coffey BJ, Park KS. Behavioral and emotional aspects of Tourette syndrome. Neurol Clin. 1997 May;15(2):277–89.
16.Zinner SH.Tourette disorder. Pediatr Rev. 2000;21(11):372–83.
17.Hawley, JS. Tourette Syndrome. eMedicine (June 23, 2008). Retrieved on August 10, 2009.
18.Stern JS, Burza S, Robertson MM. Gilles de la TS syndrome and its impact in the UK. Postgraduate Medicine Journal. 2005 Jan;81(951):12–19.
19.Leckman JF. TS syndrome. Lancet. 2002 Nov 16;360(9345):1577–86.
20.Denckla MB. Attention-deficit hyperactivity disorder (ADHD) comorbidity: a case for "pure" Tourette syndrome?. J Child Neurol. 2006 Aug;21(8):701–3.
21.Denckla MB. Attention deficit hyperactivity disorder: the childhood co-morbidity that most influences the disability burden in Tourette syndrome. Adv Neurol. 2006;99:17–21.
22.Robertson MM. The prevalence and epidemiology of Gilles de la Tourette syndrome. Part 2: tentative explanations for differing prevalence figures in GTS, including the possible effects of psychopathology, aetiology, cultural differences, and differing phenotypes. J Psychosom Res. 2008 Nov;65(5):473–86.
23.Walkup, JT, Mink, JW, Hollenback, PJ, (eds). Advances in Neurology, Tourette syndrome. Lippincott, Williams & Wilkins, Philadelphia, PA. 2006;99:xv.
24.O'Rourke JA, Scharf JM, Yu D, et al. The genetics of Tourette syndrome: A review. J Psychosom Res. 2009 Dec;67(6):533–545
25.Mejia NI, Jankovic J. Secondary tics and tourettism. Rev Bras Psiquiatr. 2005;27(1):11–17.
26.van de Wetering BJ, Heutink P. The genetics of the Gilles de la Tourette syndrome: a review. J Lab Clin Med. 1993 May;121(5):638–45.
27.Tourette Syndrome: Frequently Asked Questions. Tourette Syndrome Association. Retrieved on December 29, 2011.
28. Black, KJ. Tourette Syndrome and Other Tic Disorders. eMedicine (March 22, 2006). Retrieved on June 27, 2006.
29.Swerdlow, NR. Tourette Syndrome: Current Controversies and the Battlefield Landscape. Curr Neurol Neurosci Rep. 2005, 5:329–31.
30.Pauls DL, Towbin KE, Leckman JF, et al. Gilles de la TS syndrome and obsessive–compulsive disorder. Evidence supporting a genetic relationship. Arch Gen Psychiatry. 1986 Dec;43(12):1180–82.
31.Miguel EC, do Rosario-Campos MC, Shavitt RG, et al. The tic-related obsessive–compulsive disorder phenotype and treatment implications. Adv Neurol. 2001;85:43–55.
32.Peterson BS, Cohen DJ. The treatment of TS Syndrome: multimodal, developmental intervention. J Clin Psychiatry. 1998;59 Suppl 1:62–72.
33.Harris K, Singer HS. Tic disorders: neural circuits, neurochemistry, and neuroimmunology. J Child Neurol. 2006;21(8):678-89.
34.Leckman JF, Bloch MH, Smith ME, et al. Neurobiological substrates of Tourette's disorder, J Child Adolesc Psychopharmacol. 2010 ;20(4):237-47
35.Mazzone L,Yu S,Blair C,et al. An FMRI study of frontostriatal circuits during the inhibition of eye blinking in persons with Tourette syndrome. Am J Psychiatry.2010,167(3 ):341-9.
36.Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989,12(10):366-375.
37.Mink J. W. The basal ganglia and involuntary movements:Impaired inhibition of competing motor patterns. Arch. Neurol. 2003; 60,1365–1368.
38.Mink J.W. Basal ganglia dysfunction in Tourette’s syndrome:a new hypothesis. Pediatr. Neurol. 2001;25, 190–198
39.Albin RL, Mink JW. Recent advances in Tourette syndrome research. Trends Neurosci 2006; 29:175–182.
40.Stern E, Silbersweig DA, Chee KY, et al. A functional neuroanatomy of tics in Tourette syndrome. Arch Gen Psychiatry 2000; 57:741–748.
41.Peterson BS, Skudlarski P, Anderson AW, et al. A functional magnetic resonance imaging study of tic suppression in Tourette syndrome. Arch Gen Psychiatry 1998; 55:326–333.
42.Kalanithi PS, Zheng W, Kataoka Y, et al. Altered parvalbumin-positive neuron distribution in basal ganglia of individuals with Tourette syndrome. Proc Natl Acad Sci U S A 2005; 102:13307–13312.
43.Kataoka Y, Kalanithi PS, Grantz H, et al. Decreased number of parvalbumin and cholinergic interneurons in the striatum of individuals with Tourette syndrome. J Comp Neurol 2010; 518:277–291.
44.Leckman JF. Tourette’s syndrome. Lancet 2002; 360:1577–1586.
45.Whitaker AH, Van Rossem R, Feldman JF, et al. Psychiatric outcomes in low birth-weight children at age 6 years: relation to neonatal cranial ultrasound abnormalities. Arch Gen Psychiatry 1997; 54:847–856.
46.Mathews CA, Bimson B, Lowe TL, et al. Association between maternal smoking and increased symptom severity in Tourette’s syndrome. Am J Psychiatry 2006; 163:1066–1073.
47.Fagel DM, Ganat Y, Cheng E, et al. Fgfr1 is required for cortical regeneration and repair after perinatal hypoxia. J Neurosci 2009; 29:1202–1211.
48.Singer HS. Tourette’s syndrome: from behaviour to biology. Lancet Neurol 2005; 4:149–159.
49.Threlfell S, Clements MA, Khodai T, et al. Striatal muscarinic receptors promote activity dependence of dopamine transmission via distinct receptor subtypes on cholinergic interneurons in ventral versus dorsal striatum. J Neurosci 2010; 30:3398–3408.
50.Morris G, Arkadir D, Nevet A, et al. Coincident but distinct messages of midbrain dopamine and striatal tonically active neurons. Neuron 2004; 43:133–143.
51.Price RA, Kidd KK, Cohen DJ, et al. A twin study of Tourette syndrome. Arch Gen Psychiatry 1985; 42:815–820.
52.Walkup JT, LaBuda MC, Singer HS, et al. Family study and segregation analysis of Tourette syndrome: evidence for a mixed model of inheritance. Am J Hum Genet 1996; 59:684–693.
53.Kurlan R, Eapen V, Stern J, et al. Bilineal transmission in Tourette’s syndrome families. Neurology 1994; 44:2336–2342.
54.Hasstedt SJ, Leppert M, Filloux F, et al. Intermediate inheritance of Tourette syndrome, assuming assortative mating. Am J HumGenet 1995; 57:682–689.
55.Sundaram SK, Huq AM, Wilson BJ, Chugani HT. Tourette syndrome is associated with recurrent exonic copy number variants. Neurology 2010; 74:1583–1590.
56.Verkerk AJ, Mathews CA, Joosse M, et al. CNTNAP2 is disrupted in a family with Gilles de la Tourette syndrome and obsessive compulsive disorder. Genomics 2003; 82:1–9.
57.Lawson-Yuen A, Saldivar JS, Sommer S, Picker J. Familial deletion within NLGN4 associated with autism and Tourette syndrome. Eur J Hum Genet 2008; 16:614–618.
58.Ercan-Sencicek AG, Stillman AA, Ghosh AK, et al. L-histidine decarboxylase and Tourette’s syndrome. N Engl J Med 2010; 362:1901–1908.60 Leckman JF, Bloch MH, King RA, et al."Phenomenology of tics and natural history of tic disorders. Adv Neurol. 2006;99:1–16.
59.Leckman JF, Bloch MH, King RA, et al."Phenomenology of tics and natural history of tic disorders. Adv Neurol. 2006;99:1–16.61
60.Bagheri MM, Kerbeshian J, Burd L. Recognition and management of TS syndrome and tic disorders. American Family Physician. 1999; 59:2263–74.
61.The Tourette Syndrome Classification Study Group. Definitions and classification of tic disorders. Arch Neurol. 1993 Oct;50(10):1013–16.
62.Dure LS 4th, DeWolfe J. Treatment of tics. Adv Neurol. 2006;99:191–96.
63.Malone DA Jr, Pandya MM. Behavioral neurosurgery. Adv Neurol. 2006;99:241–47.
64.Jankovic J. Differential diagnosis and etiology of tics. Adv Neurol. 2001;85:15–29.
65.Cohen AJ, Leckman JF. Sensory phenomena associated with Gilles de la TS syndrome. J Clin Psychiatry. 1992 Sep; 53(9):319–23.
66.Prado HS, Rosário MC, Lee J, et al. Sensory phenomena in obsessive–compulsive disorder and tic disorders: a review of the literature. CNS Spectr. 2008;13(5):425–32.
67.Bliss J. Sensory experiences of Gilles de la Tourette syndrome.Arch Gen Psychiatry. 1980 Dec; 37(12):1343–47.
68.Kwak C, Dat Vuong K, Jankovic J. Premonitory sensory phenomenon in TS syndrome.Mov Disord. 2003 Dec;18(12):1530–33.
69.Scahill LD, Leckman JF, Marek KL. Sensory phenomena in TS syndrome. Adv Neurol.1995; 65:273–80.
70.Miguel EC, do Rosario-Campos MC, Prado HS, et al. Sensory phenomena in obsessive–compulsive disorder and TS disorder. J Clin Psychiatry. 2000 Feb;61(2):150–56.
71.Rapin I. Autism spectrum disorders: relevance to Tourette syndrome. Adv Neurol. 2001;85:89–101.
72.Spencer T, Biederman J, Harding M, et al. Disentangling the overlap between TS disorder and ADHD". J Child Psychol Psychiatry. 1998 Oct;39(7):1037–44.
73.Summary of Practice: Relevant changes to DSM-IV-TR. American Psychiatric Association. Retrieved from May 11, 2008
74.Scahill L, Erenberg G, Berlin CM Jr, et al. Tourette Syndrome Association Medical Advisory Board: Practice Committee. Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx. 2006 Apr;3(2):192–206.
75.Ringman JM, Jankovic J. Occurrence of tics in Asperger's syndrome and autistic disorder. J Child Neurol. 2000 Jun;15(6):394–400.
76.Jankovic J, Mejia NI. Tics associated with other disorders. Adv Neurol. 2006;99:61–68.
77.Freeman, RD. TS Syndrome: minimizing confusion. Roger Freeman, MD, blog. Retrieved on February 8, 2006.
78.Robertson MM. Tourette syndrome, associated conditions and the complexities of treatment. Brain. 2000;123 Pt 3:425–62.
79.Schapiro NA. Dude, you don't have TS: TS syndrome, beyond the tics. Pediatr Nurs. 2002; 28(3):243–46, 249–53.
80.Coffey BJ, Shechter RL. Treatment of co-morbid obsessive compulsive disorder, mood, and anxiety disorders. Adv Neurol. 2006; 99:208–21.
81.Himle MB, Woods DW, Piacentini JC. et al. Brief review of habit reversal training for tourette syndrome. J Child Neurol. 2006 Aug;21(8):719–25.
82.Woods DW, Himle MB, Conelea CA. Behavior therapy: other interventions for tic disorders. Adv Neurol. 2006; 99:234–40.
83.Pappert EJ, Goetz CG, Louis ED, et al. Objective assessments of longitudinal outcome in Gilles de la TS syndrome. Neurology. 2003 Oct 14;61(7):936–40.
84.Singer HS. TS syndrome: from behaviour to biology. Lancet Neurol. 2005 Mar;4(3):149–59.
85.Burd L, Kerbeshian PJ, Barth A, et al. Long-term follow-up of an epidemiologically defined cohort of patients with Tourette syndrome. J Child Neurol. 2001;16(6):431–37.
86.Leckman JF, Cohen DJ. TS Syndrome—Tics, Obsessions, Compulsions: Developmental Psychopathology and Clinical Care. John Wiley & Sons, Inc., New York. 1999:37.
87.Cohen DJ, Leckman JF, Pauls D. Neuropsychiatric disorders of childhood: TS syndrome as a model. Acta Paediatr Suppl 1997,422; 106–11.
88.Fuyong Jiao ,Xianpeng Yan ,Ru Xue, Jing Lin,Tourette treatment progress .China Medicine and Pharmacy. 2012;2 (23):52-54.
89.Fuyong Jiao,Li Wei,Jing Lin et al. Clincal assessment of treatment of Tourette Syndrome in Chinese children with Clonidine transdermal patch , Journal of the Polish society of Child Neurology ,2011;20 (40):15-19, 20.
90.Ya-song Du, Hua-fang Li, Alasdair Vance, Fu-yong Jiao et al .Randomized double-blind multicentre placebo-controlled clinical trial of the Clonidine adhesive patch for the treatment of tic disorders, Australian and New Zealand Journal of Psychiatry 2008; 42:807-813.
Article citation:
Jiao Fuyong,Guo Xiangyang,Yan Xianpeng,Wei Li. Update situation of Tourette syndrome. J Pharm Biomed Sci 2014; 04(04): 327-337. Available at www.jpbms.info.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Copyright © 2014 Jiao Fuyong,Guo Xiangyang,Yan Xianpeng,Wei Li. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.